As has been broadly announced, Canada, the United States, and Mexico are currently renegotiating the North America Free Trade Agreement. At several times during the 2016 U.S. presidential campaign and as recently as January of this year, Donald Trump has announced that terminating the agreement is one possible alternative.
A termination would have severe impacts on several aspects of the economy throughout North America; The purpose of this article is to look at the relevant consequences concerning intellectual property protection afforded to pharmaceutical products in Mexico, which has risen to high standards either as a direct consequence of NAFTA or as part of an overall NAFTA environment.

Continue reading this story by Juan Luis Serrano-Leets from Sanchez Devanny with no paywalls by following this link.